# A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

> **NCT03941574** · PHASE2 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 108 (estimated)

## Conditions studied

- MSI-H Solid Malignant Tumor

## Interventions

- **DRUG:** HLX10

## Key facts

- **NCT ID:** NCT03941574
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-07-15
- **Primary completion:** 2024-05-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2022-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03941574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03941574, "A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03941574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*